Michael A Barry

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6495808/publications.pdf

Version: 2024-02-01

105	6,233	87888	69250
papers	citations	38 h-index	77 g-index

109	109	109	5842
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochemical Pharmacology, 1990, 40, 2353-2362.	4.4	845
2	Toward cellâ€“targeting gene therapy vectors: Selection of cellâ€“binding peptides from random peptideâ€“presenting phage libraries. Nature Medicine, 1996, 2, 299-305.	30.7	343
3	Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nature Reviews Microbiology, 2008, 6, 529-540.	28.6	342
4	Protection against mycoplasma infection using expression-library immunization. Nature, 1995, 377, 632-635.	27.8	313
5	Poly(ethylenimine)-mediated transfection: A new paradigm for gene delivery. Journal of Biomedical Materials Research Part B, 2000, 51, 321-328.	3.1	293
6	Lentiviral vectors: basic to translational. Biochemical Journal, 2012, 443, 603-618.	3.7	258
7	Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Molecular Therapy, 2005, 11, 66-79.	8.2	225
8	Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. Journal of Biomedical Optics, 2007, 12, 024017.	2.6	193
9	Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting. Current Gene Therapy, 2007, 7, 189-204.	2.0	174
10	Semaphorin III can repulse and inhibit adult sensory afferents in vivo. Nature Medicine, 1997, 3, 1398-1401.	30.7	135
11	Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting. Current Gene Therapy, 2011, 11, 241-258.	2.0	131
12	IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis. Gastroenterology, 2020, 159, 1487-1503.e17.	1.3	105
13	Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Molecular Therapy, 2003, 8, 688-700.	8.2	104
14	Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus. Human Gene Therapy, 2009, 20, 975-988.	2.7	101
15	Modification of Adenoviral Vectors With Polyethylene Glycol Modulates In Vivo Tissue Tropism and Gene Expression. Molecular Therapy, 2008, 16, 1276-1282.	8.2	95
16	Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Molecular Therapy, 2004, 9, 942-954.	8.2	87
17	Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus. Cancer Research, 2008, 68, 5896-5904.	0.9	86
18	A chimeric adenovirus vector encoding reovirus attachment protein Â1 targets cells expressing junctional adhesion molecule 1. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6188-6193.	7.1	79

#	Article	IF	Citations
19	Generation of a Kupffer Cell-evading Adenovirus for Systemic and Liver-directed Gene Transfer. Molecular Therapy, 2011, 19, 1254-1262.	8.2	77
20	Metabolic Biotinylation of Secreted and Cell Surface Proteins from Mammalian Cells. Biochemical and Biophysical Research Communications, 2001, 281, 993-1000.	2.1	72
21	Polyethylene Glycol Modification of Adenovirus Reduces Platelet Activation, Endothelial Cell Activation, and Thrombocytopenia. Human Gene Therapy, 2007, 18, 837-848.	2.7	72
22	Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo. Journal of Virology, 2009, 83, 5648-5658.	3.4	72
23	Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors. Journal of Virology, 2012, 86, 2293-2301.	3.4	69
24	Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology, 2006, 349, 453-462.	2.4	67
25	Cryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses. Science Advances, 2017, 3, e1602670.	10.3	64
26	Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology, 2009, 394, 311-320.	2.4	61
27	Comparison of Replication-Competent, First Generation, and Helper-Dependent Adenoviral Vaccines. PLoS ONE, 2009, 4, e5059.	2.5	61
28	An optimized method for the chemiluminescent detection of alkaline phosphatase levels during osteodifferentiation by bone morphogenetic protein 2. Journal of Cellular Biochemistry, 2001, 80, 532-537.	2.6	60
29	Metabolic Biotinylation of Recombinant Proteins in Mammalian Cells and in Mice. Molecular Therapy, 2000, 1, 96-104.	8.2	59
30	Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine, 2007, 25, 8687-8701.	3.8	52
31	Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin. PLoS ONE, 2011, 6, e18314.	2.5	51
32	Effects of Shielding Adenoviral Vectors with Polyethylene Glycol on Vector-Specific and Vaccine-Mediated Immune Responses. Human Gene Therapy, 2008, 19, 1369-1382.	2.7	50
33	Circulating Antibodies and Macrophages as Modulators of Adenovirus Pharmacology. Journal of Virology, 2013, 87, 3678-3686.	3.4	49
34	Comparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Associated Virus, and Lentiviral Vectors After Intravenous and Direct Kidney Injections. Human Gene Therapy, 2019, 30, 1559-1571.	2.7	47
35	Generation of a Hypomorphic Model of Propionic Acidemia Amenable to Gene Therapy Testing. Molecular Therapy, 2013, 21, 1316-1323.	8.2	46
36	Infectious SIV resides in adipose tissue and induces metabolic defects in chronically infected rhesus macaques. Retrovirology, 2016, 13, 30.	2.0	46

#	Article	IF	Citations
37	Infection and Killing of Multiple Myeloma by Adenoviruses. Human Gene Therapy, 2010, 21, 179-190.	2.7	44
38	Low Seroprevalent Species D Adenovirus Vectors as Influenza Vaccines. PLoS ONE, 2013, 8, e73313.	2.5	44
39	Adeno-Associated Virus Serotype 8 Gene Transfer Rescues a Neonatal Lethal Murine Model of Propionic Acidemia. Human Gene Therapy, 2011, 22, 477-481.	2.7	39
40	Species D Adenoviruses as Oncolytics against B-cell Cancers. Clinical Cancer Research, 2011, 17, 6712-6722.	7.0	39
41	Suppression-Replacement KCNQ1 Gene Therapy for Type 1 Long QT Syndrome. Circulation, 2021, 143, 1411-1425.	1.6	39
42	Precision gene editing technology andÂapplications in nephrology. Nature Reviews Nephrology, 2018, 14, 663-677.	9.6	38
43	Amplified and Persistent Immune Responses Generated by Single-Cycle Replicating Adenovirus Vaccines. Journal of Virology, 2015, 89, 669-675.	3.4	37
44	Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses. Journal of Virology, 2017, 91, .	3.4	36
45	Expanded Anticancer Therapeutic Window of Hexon-modified Oncolytic Adenovirus. Molecular Therapy, 2009, 17, 2121-2130.	8.2	35
46	IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology, 2014, 462-463, 158-165.	2.4	35
47	Long-Term Sex-Biased Correction of Circulating Propionic Acidemia Disease Markers by Adeno-Associated Virus Vectors. Human Gene Therapy, 2015, 26, 153-160.	2.7	35
48	Rapid Construction of Capsid-Modified Adenoviral Vectors Through Bacteriophage Î» Red Recombination. Human Gene Therapy, 2004, 15, 1125-1130.	2.7	34
49	Development and characterization of enhanced green fluorescent protein and luciferase expressing cell line for non-destructive evaluation of tissue engineering constructs. Biomaterials, 2004, 25, 5809-5819.	11.4	33
50	Cryoelectron Microscopy of Protein IX-Modified Adenoviruses Suggests a New Position for the C Terminus of Protein IX. Journal of Virology, 2006, 80, 11881-11886.	3.4	33
51	Short-Term Rescue of Neonatal Lethality in a Mouse Model of Propionic Acidemia by Gene Therapy. Human Gene Therapy, 2009, 20, 169-180.	2.7	33
52	Characterization of species C human adenovirus serotype 6 (Ad6). Virology, 2011, 412, 19-27.	2.4	32
53	Expression library immunization to discover and improve vaccine antigens. Immunological Reviews, 2004, 199, 68-83.	6.0	30
54	Selection of Muscle-Binding Peptides from Context-Specific Peptide-Presenting Phage Libraries for Adenoviral Vector Targeting. Journal of Virology, 2005, 79, 13667-13672.	3.4	27

#	Article	IF	Citations
55	Retargeting adenoviruses for therapeutic applications and vaccines. FEBS Letters, 2020, 594, 1918-1946.	2.8	27
56	Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses, 2009, 1, 920-938.	3.3	26
57	Targeting Adenoviruses with Factor Xâ€“Single-Chain Antibody Fusion Proteins. Human Gene Therapy, 2010, 21, 739-749.	2.7	26
58	Single-cycle adenovirus vectors in the current vaccine landscape. Expert Review of Vaccines, 2018, 17, 1-11.	4.4	25
59	Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein. Vaccine, 2014, 32, 6934-6940.	3.8	23
60	Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16008.	4.1	23
61	Biotinylated gene therapy vectors. Expert Opinion on Biological Therapy, 2003, 3, 925-940.	3.1	22
62	Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV. PLoS ONE, 2013, 8, e67574.	2.5	22
63	Increased Transduction of Skeletal Muscle Cells by Fibroblast Growth Factor-Modified Adenoviral Vectors. Human Gene Therapy, 2006, 17, 314-320.	2.7	20
64	Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant. Vaccines, 2014, 2, 686-706.	4.4	20
65	Selection of chronic lymphocytic leukemia binding peptides. Cancer Research, 2003, 63, 5213-7.	0.9	20
66	Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers. Molecular Therapy - Oncolytics, 2016, 3, 15021.	4.4	19
67	Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors. Genes, 2017, 8, 79.	2.4	19
68	Improving Molecular Therapy in the Kidney. Molecular Diagnosis and Therapy, 2020, 24, 375-396.	3.8	18
69	Real-Time Dynamic Imaging of Virus Distribution In Vivo. PLoS ONE, 2011, 6, e17076.	2.5	18
70	Dysregulated miRNAs and their pathogenic implications for the neurometabolic disease propionic acidemia. Scientific Reports, 2017, 7, 5727.	3.3	16
71	Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer. Oncolytic Virotherapy, 2018, Volume 7, 43-51.	6.0	14
72	A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. Journal of Infectious Diseases, 2018, 218, 1883-1889.	4.0	14

#	Article	IF	Citations
73	Systemic delivery of therapeutic viruses. Current Opinion in Molecular Therapeutics, 2009, 11, 411-20.	2.8	14
74	Effects of Adeno-Associated Virus Serotype and Tissue-Specific Expression on Circulating Biomarkers of Propionic Acidemia. Human Gene Therapy, 2014, 25, 837-843.	2.7	13
75	CD46-Mediated Transduction of a Species D Adenovirus Vaccine Improves Mucosal Vaccine Efficacy. Human Gene Therapy, 2014, 25, 364-374.	2.7	13
76	Structure-based assessment of protein-protein interactions and accessibility of protein IX in adenoviruses with implications for antigen display. Virology, 2018, 516, 102-107.	2.4	13
77	Mining the Adenovirus "Virome" for Systemic Oncolytics. Current Pharmaceutical Biotechnology, 2012, 13, 1804-1808.	1.6	12
78	A Vectorâ€“Host System to Fingerprint Virus Tropism. Human Gene Therapy, 2012, 23, 1116-1126.	2.7	12
79	Comparison of Adenoviruses as Oncolytics and Cancer Vaccines in an Immunocompetent B Cell Lymphoma Model. Human Gene Therapy, 2011, 22, 1095-1100.	2.7	11
80	Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. Journal of Virology, 2019, 93, .	3.4	11
81	Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope. Vaccines, 2020, 8, 64.	4.4	11
82	Retargeted and detargeted adenovirus for gene delivery to the muscle. Virology, 2018, 514, 118-123.	2.4	10
83	Mucoadhesive wafers composed of binary polymer blends for sublingual delivery and preservation of protein vaccines. Journal of Controlled Release, 2021, 330, 427-437.	9.9	10
84	Structural Organization and Protein-Protein Interactions in Human Adenovirus Capsid. Sub-Cellular Biochemistry, 2021, 96, 503-518.	2.4	10
85	Metabolic perturbations mediated by propionyl-CoA accumulation in organs of mouse model of propionic acidemia. Molecular Genetics and Metabolism, 2021, 134, 257-266.	1.1	10
86	Ex VivoandIn VivoCD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26). Journal of Virology, 2022, 96, JVI0082621.	3.4	9
87	Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human Cells. Journal of Virology, 2015, 89, 12401-12417.	3.4	8
88	Comparison of systemic and mucosal immunization with replicating Single cycle Adenoviruses. Global Vaccines and Immunology, 2018, 3, .	0.2	8
89	Mucosal vaccination by adenoviruses displaying reovirus sigma 1. Virology, 2015, 482, 60-66.	2.4	7
90	Imaging Luciferase-Expressing Viruses. Methods in Molecular Biology, 2012, 797, 79-87.	0.9	6

#	Article	IF	Citations
91	Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5. Biomedicines, 2017, 5, 46.	3.2	5
92	Breaking tolerance with engineered class I antigen-presenting molecules. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3136-3145.	7.1	5
93	A Replicating Single-Cycle Adenovirus Vaccine Effective against Clostridium difficile. Vaccines, 2020, 8, 470.	4.4	5
94	Poly(ethylenimine)â€mediated transfection: A new paradigm for gene delivery. Journal of Biomedical Materials Research Part B, 2000, 51, 321-328.	3.1	5
95	Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L. Human Gene Therapy, 2022, 33, 250-261.	2.7	5
96	Selection of Peptides on Phage. , 2003, , 547-579.		3
97	Response to Adhikary et al.. Virology, 2012, 424, 2.	2.4	3
98	Minimally invasive monitoring of CD4 T cells at multiple mucosal tissues after intranasal vaccination in rhesus macaques. PLoS ONE, 2017, 12, e0188807.	2.5	3
99	An optimized method for the chemiluminescent detection of alkaline phosphatase levels during osteodifferentiation by bone morphogenetic protein 2. , 2001, 80, 532.		2
100	Short-term Rescue of Neonatal Lethality in a Mouse Model of Propionic Acidemia by Gene Therapy. Human Gene Therapy, 2008, .	2.7	2
101	A novel codon-optimized SIV gag-pol immunogen for gene-based vaccination. Virology Reports, 2015, 5, 47-55.	0.4	1
102	Unlocking loxP to Track Genome Editing In Vivo. Genes, 2021, 12, 1204.	2.4	1
103	Refined Capsid Structure of Human Adenovirus D26 at 3.4 Ã... Resolution. Viruses, 2022, 14, 414.	3.3	1
104	Adenoviral Vector Targeting via Mitigation of Liver Sequestration. , 2016, , 293-317.		0
105	Recent advances towards gene therapy for propionic acidemia: translation to the clinic. Expert Review of Precision Medicine and Drug Development, 2019, 4, 229-237.	0.7	0